Prostate cancer is the second most diagnosed cancer of men all over the world. In the last
few decades, new imaging techniques based on Magnetic Resonance Imaging (MRI) have …

We review the recent advances in the genomic understanding of human prostate cancer,
with focus on molecular subclassification. Broadly, prostate cancer can be classified based …

Next-generation sequencing (NGS) has enabled genome-wide personalized oncology
efforts at centers and companies with the specialty expertise and infrastructure required to …

Objectives To use a non‐biased assay for circulating tumour cells (CTCs) in patients with
prostate cancer (PCa) in order to identify non‐traditional CTC phenotypes potentially …

Objectives Prostate cancer has a variable clinical course, and molecular characterization
has revealed striking mutational heterogeneity that may underlie the unpredictable clinical …

Prostate cancer (CaP) is the second most diagnosed cancer in men all over the world. In the
last decades, new imaging techniques based on magnetic resonance imaging (MRI) have …

BACKGROUND ERG rearrangements in localized prostate cancer can be detected with high
sensitivity and specificity by immunohistochemistry (IHC). However, recent data suggest that …

Prostate cancer (CaP) is the second most diagnosed cancer in men all over the world. CaP
growth is characterized by two main types of evolution:(i) the slow-growing tumours progress …

Molecular prostate cancer subtypes have been proposed on the basis of mutually exclusive
SPINK1 and ERG overexpression, with conflicting reports on their prognostic ability. Flavin …

Background. New cancer biomarkers are being discovered at a rapid pace; however, these
tests vary in their predictive performance characteristics, and it is unclear how best to use …